Post-Market Review of Pulmonary Arterial Hypertension Medicines – Public Consultation Process
Page last updated: 26 July 2017
The public consultation process on the Post-Market Review of the Pulmonary Arterial Hypertension medicines has now closed.
The Department appreciates the contributions of all organisations and individuals who made a submission.
An additional medicine, riociguat, has been added to the Review. The sponsor of this medicine, and stakeholders who have previously provided a submission, were invited to update their submission if required.
Submissions commenting on the Review’s Terms of Reference have now been published.